Cargando…
Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets
Tyrosine kinase inhibitors (TKI) such as the BCR-ABL inhibitor dasatinib and nilotinib are highly effective therapies for chronic myeloid leukemia (CML). However, several lines of evidence suggest that dasatinib can induce bleeding which may be due to impaired collagen-induced platelet adhesion, agg...
Autores principales: | Beke Debreceni, Ildikó, Mezei, Gabriella, Batár, Péter, Illés, Árpád, Kappelmayer, János |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862041/ https://www.ncbi.nlm.nih.gov/pubmed/31683623 http://dx.doi.org/10.3390/ijms20215430 |
Ejemplares similares
-
The Phosphatase Inhibitor Calyculin-A Impairs Clot Retraction, Platelet Activation, and Thrombin Generation
por: Hudák, Renáta, et al.
Publicado: (2017) -
Flow Cytometric Investigation of Classical and Alternative Platelet Activation Markers
por: Nagy, Béla, et al.
Publicado: (2013) -
The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021) -
Haemodiafiltration elicits less platelet activation compared to haemodialysis
por: Becs, Gergely, et al.
Publicado: (2016) -
Measurement of Soluble Biomarkers by Flow Cytometry
por: Antal-Szalmás, Péter, et al.
Publicado: (2013)